A common feline heart disease medication may not be so effective in some cats, study shows
Genetic mutations in some cats could affect how well they respond to a common medication used to treat feline heart disease, a new study from the University of California, Davis shows.
The medication, called clopidogrel (brand name Plavix), is prescribed by practitioners around the world to treat hypertrophic cardiomyopathy. It’s meant to prevent blood clots caused by the disease.
“We were consistently seeing cats that, despite being on clopidogrel, were still forming blood clots,” said the study’s corresponding author, Josh Stern. He and the other researchers identified mutations in cats that they say could reduce the drug’s effectiveness.
The researchers hope that in the future, veterinarians will be able to rapidly test cats with hypertrophic cardiomyopathy for these mutations when they’re deciding what to prescribe.
“We are very excited to be approaching this era where personalized or precision medicine in animals can catch up to precision medicine in humans,” said study coauthor Ronald Li. “Just as we can’t expect every human to respond to medication in the same way, we can’t expect all cats to respond the same way either.”